Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | Do not list | Complete | ||
Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder, Adult | Do not list | Complete | ||
Tridural | Tramadol hydrochloride | Pain | Do not list | Complete | ||
Rasilez | Aliskiren | Hypertension | Do not list | Complete | ||
Exelon Patch | Rivastigmine | Dementia (Alzheimer's type) | Do not list | Complete | ||
Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | Do not list | Complete | ||
Cymbalta | Duloxetine hydrochloride | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | ||
Thelin | Sitaxsentan sodium | Pulmonary arterial hypertension (WHO class II and III) | Do not list | Complete | ||
Relistor | Methylnaltrexone bromide | Constipation, Opioid-induced | Do not list | Complete |